[Pancreatic panniculitis with intraductal carcinoid tumor of the pancreas divisum]. / Panniculite nodulaire et tumeur carcinoïde intracanalaire d'un pancréas divisum.

BACKGROUND: The association of pancreatic diseases with panniculitis are rare. Various pancreatic diseases are described with panniculitis of which most frequent are pancreatitis and acinar cell carcinoma. We report a case of an acute nodular panniculitis whose etiologic assessment allow of discover an intraductal carcinoid tumour on a pancreas divisum. CASE REPORT: A 45 year-old woman without notable medico-surgical history had suddenly presented with multiple cutaneous erythematous nodules on the legs associated with moderates arthralgia in the wrists and the ankles. There were no other clinical manifestations. Results of laboratory tests and chest X-ray were normal. Histologic exploration showed a centrolobular fat necrosis and suggestive pancreatic disease was confirmed by an increase in serum pancreatic enzymes. Ultrasound study and computerized tomography of the abdomen was without notable anomaly. Endoscopic ultrasound study of the pancreas and magnetic resonance imaging showed moderate distention of the pancreatic duct. Endoscopic retrograde cholangiopancreatography highlighted a small tumor in the accessory duct orifice of the pancreas divisum. Immunohistological study of tumor's biopsy showed a carcinoid tumor. DISCUSSION: To our knowledge, this observation describes the first case of nodular panniculitis associated with carcinoid tumor of the pancreas. The detection of this tumor at an early stage, revealed by cutaneous fat necrosis, is probably due to the unusual anatomic site, on the accessory papilla of the pancreas divisum.

[Cutaneous reactions or necrosis from interferon alpha: can interferon be reintroduced after healing? Six case reports]. / Réactions cutanées ou nécrose à l'interféron alpha: peut-on reprendre l'interféron? A propos de six cas.

PURPOSE: Alpha, beta or gamma interferon (INF) are cytokines produced by cells in response to antigenic stimulation. They are used to treat various hepatic, hematological, oncological and neurological diseases. Cutaneous reactions (rash, alopecia, labial herpes, erythema, or induration at the site of injection, and more rarely cutaneous necrosis) represent 5 to 12% of side-effects observed in patients receiving INF. The authors report six cases of local cutaneous reactions to alpha INF, five of which corresponded to cutaneous necrosis. This makes them question the relevance of INF reintroduction. METHODS: The study included 5 male and 1 female patients (mean age: 59.1 years; range: 42 to 74 years old). Three patients had chronic hepatitis C, while three others presented a blood disease. RESULTS: Cutaneous necrosis occurred after 1 to 10 months of treatment. The mean time to healing was 16.2 weeks. Reintroduction of the drug including injection in other sites did not lead to recurrence of necrosis in five out of the six cases. CONCLUSION: INF-induced cutaneous necrosis does not depend on the type of INF, the site of injection, the dose and may occur 2 months to 9 years after treatment implementation. The exact mechanisms involved in cutaneous necrosis remain unknown. Morbidity is due to a very long time to healing (4 to 6 months). Futhermore, healing sometimes requires prior surgery. Physicians should be aware of the potential occurrence of erythema in patients treated by INF, as it is the first sign of necrosis. The site of injection should then be modified. In case of necrosis, risk factors for thrombophilia, factors reducing microcirculation (DHE, beta-blockers, cigarette smoking) should be investigated. INF injections should be cautiously reintroduced in other sites with the help of a nurse in case of self-injections prior to the occurrence of necrosis. Regarding self-injections patients' training should be emphasized.